Inflammation in multiple sclerosis: The good, the bad, and the complex

Lancet Neurology

Volumn 1, Issue 8, 2002, Pages 499-509

  Martino, Gianvito ^a   Adorini, Luciano ^b   Rieckmann, Peter ^c   Hillert, Jan ^d   Kallmann, Boris ^c   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b BioXell SpA   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CASPASE INHIBITOR; CD152 IMMUNOGLOBULIN; CD29 MONOCLONAL ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CLADRIBINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLATIRAMER; GLUCOCORTICOID; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERFERON BETA SERINE; LENERCEPT; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELIN; MYELIN BASIC PROTEIN; PEPTIDE CDR2; RECEPTOR BLOCKING AGENT; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DEMYELINATION; DIAGNOSTIC IMAGING; DISEASE COURSE; FIBROSIS; GENE; GENETICS; GENOTYPE; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; METABOLISM; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; VACCINATION; BRAIN; IMAGE QUALITY; IMMUNOLOGY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; RADIOGRAPHY;

BRAIN; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; RADIOGRAPHIC IMAGE ENHANCEMENT;

EID: 0038240048     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00223-5     Document Type: Review

References (128)

1. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr Opin Neurol. 12:1999;309-321.
2. Lucchinetti C.F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:1996;259-274.
3. Kieseier B.C., Storch M.K., Archelos J.J., Martino G., Hartung H.P. Effector pathways in immune mediated central nervous system demyelination. Curr Opin Neurol. 12:1999;323-336.
4. Compston A., Coles A. Multiple sclerosis. Lancet. 359:2002;1221-1231.
5. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 37:1995;424-435.
6. 2+ influx in T lymphocytes from patients with multiple sclerosis. Proc Natl Acad Sci USA. 91:1994;4825-4829.
7. Esiri M.M., Gay D. The immunocytochemistry of multiple sclerosis plaques. Raine C.S., McFarland H.F., Tourtellotte W.W. Multiple sclerosis: clinical and pathogenetic basis. 1997;173-186 Chapman & Hall, London.
8. Franciotta D.M., Martino G., Zardini E., et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol. 115:2001;192-198.
9. Martino G., Grohovaz F., Brambilla E., et al. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann Neurol. 43:1998;340-349.
10. Franciotta D.M., Grimaldi L.M.E., Martino G., et al. Tumor necrosis factor in MS serum and CSF. Ann Neurol. 26:1989;787-789.
11. Sørensen T.L., Tani M., Jensen J., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis. J Clin Invest. 103:1999;807-815.
12. Lassmann H. Pathology of multiple sclerosis. Compston A. McAlpine's multiple sclerosis. 1998;323-358 Churchill Livingstone, London.
13. Kallmann B.A., Hummel V., Lindenlaub T., Ruprecht K., Toyka K.V., Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain. 123:2000;687-697.
14. Hummel V., Kallmann B.A., Wagner S., et al. Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules. J Neuropathol Exp Neurol. 60:2001;320-327.
15. Minagar A., Jy W., Jimenez J.J., et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 56:2001;1319-1324.
16. Plumb J., McQuaid S., Mirakhur M., Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 12:2002;154-169.
17. Cuzner M.L., Gveric D., Strand C., et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol. 55:1996;1194-1204.
18. Aloisi F., Ria F., Adorini L. Regulation of T cell responses by central nervous system antigen presenting cells: different roles for microglia and astrocytes. Immunol Today. 3:2000;141-147.
19. Serafini B., Columba-Cabezas S., Di Rosa F., Aloisi F. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol. 157:2000;1991-2002.
20. Billiau A., Heremans H., Vandekerckhove F., et al. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol. 140:1988;1506-1510.
21. Furlan R., Brambilla E., Ruffini F., et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol. 167:2001;1821-1829.
22. Kerschensteiner M., Gallmeier E., Behrens L., et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 189:1999;865-870.
23. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I.R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 5:1999;49-55.
24. Copelman C.A., Diemel L.T., Gveric D., Gregson N.A., Cuzner M.L. Myelin phagocytosis and remyelination of macrophage-enriched central nervous system aggregate cultures. J Neurosci Res. 66:2001;1173-1178.
25. Kotter M.R., Setzu A., Sim F.J., Van Rooijen N., Franklin R.J. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia. 35:2001;204-212.
26. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 4:2001;1116-1122.
27. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. 5:1999;170-175.
28. Bieber A.J., Warrington A., Asakura K., et al. Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia. 37:2002;241-249.
29. Kassiotis G., Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implication for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 193:2001;427-434.
30. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens. 38:1991;1-15.
31. Caballero A., Alves-Leon S., Papais-Alvarenga R., Fernandez O., Navarro G., Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens. 54:1999;524-526.
32. Ligers A., Dyment D.A., Willer C.J., et al. Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis. Am J Hum Genet. 69:2001;900-903.
33. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens. 55:2000;140-148.
34. Brassat D., Azais-Vuillemin C., Yaouanq J., et al. Familial factors influence disability in MS multiplex families. Neurology. 52:1999;1632-1636.
35. Chataway J., Mander A., Robertson N., et al. Multiple sclerosis in sibling pairs: an analysis of 250 families. J Neurol Neurosurg Psychiatry. 71:2001;757-761.
36. Barcellos L.F., Oksenberg J.R., Green A.J., et al. Genetic basis for clinical expression in multiple sclerosis. Brain. 125:2002;150-158.
37. Broadley S.A., Deans J., Sawcer S.J., Clayton D., Compston D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis: a UK survey. Brain. 123:2000;1102-1111.
38. Becker K.G., Simon R.M., Bailey-Wilson J.E., et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA. 95:1998;9979-9984.
39. Merriman T.R., Cordell H.J., Eaves I.A., et al. Suggestive evidence for association of human chromosome 18q12-q21 and its orthologue on rat and mouse chromosome 18 with several autoimmune diseases. Diabetes. 50:2001;184-194.
40. Xu C., Dai Y., Lorentzen J.C., Dahlman I., Olsson T., Hillert J. Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci. Eur J Hum Genet. 9:2001;458-463.
41. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol. 48:2000;211-219.
42. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandvik B., Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci. 178:2000;132-135.
43. Weatherby S.J., Thomson W., Pepper L., et al. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol. 248:2001;304-310.
44. Hensiek A.E., Sawcer S.J., Feakes R., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry. 72:2002;184-187.
45. Giess R., Maurer M., Linker R., et al. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol. 59:2002;407-409.
46. Potter H., Wefes I.M., Nilsson L.N. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging. 22:2001;923-930.
47. Chapman J., Vinokurov S., Achiron A., et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology. 56:2001;312-316.
48. Masterman T., Zhang Z., Hellgren D., et al. APOE genotypes and disease severity in multiple sclerosis. Mult Scler. 8:2002;98-103.
49. Schmidt S., Barcellos L.F., DeSombre K., et al. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. Am J Hum Genet. 70:2002;708-717.
50. Ligers A., Teleshova N., Masterman T., Huang W.X., Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2:2001;145-152.
51. Harbo H.F., Celius E.G., Vartdal F., Spurkland A. CTLA4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens. 53:1999;106-110.
52. Ligers A., Xu C., Saarinen S., Hillert J., Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol. 97:1999;182-190.
53. Dyment D.A., Steckley J.L., Willer C.J., et al. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study. J Neuroimmunol. 123:2002;193-198.
54. Masterman T, Ligers A, Zhang Z, et al. CTLA4 polymorphisms influence disease course in multiple sclerosis. J Neuroimmunol (in press).
55. Mäurer M, Ponath A, Kruse N, Rieckmann P. CTLA4 dimorphism is associated with primary progressive multiple sclerosis. J Neuroimmunol (in press).
56. Fukazawa T., Yanagawa T., Kikuchi S., et al. CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci. 171:1999;49-55.
57. Masterman T., Hillert J. HLA-DR15 and age at onset in multiple sclerosis. Eur J Neurol. 9:2002;179-180.
58. Tofts P.S., Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging, I: fundamental concepts. Magn Reson Med. 17:1991;357-367.
59. Bradbury M. The concept of blood brain barrier. 1979;351-382 John Wiley, Chichester.
60. Brown W.J. The capillaries in acute and subacute multiple sclerosis plaques: a morphometric analysis. Neurology. 28:1978;89-92.
61. Hawkins C.P., Munro P.M.G., Mackenzie F., et al. Duration and selectivity of blood brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain. 113:1990;365-378.
62. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 34:1993;661-669.
63. Nesbit G.M., Forbes G.S., Scheithauer B.W., et al. Multiple sclerosis: histopathological and MR and/or CT correlation in 37 cases at biopsy and 3 cases at autopsy. Radiology. 180:1991;467-474.
64. Hawkins C.P., Mackenzie F., Tofts P., et al. Patterns of blood brain barrier breakdown in inflammatory demyelination. Brain. 114:1991;801-810.
65. Lassman H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. 1983;Springer, Berlin.
66. Dousset V., Brochet B., Vital A., et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. Am J Neuroradiology. 16:1995;225-231.
67. Seeldrayers P.A., Syha J., Morrissey S.P., et al. Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis. J Neuroimmunol. 46:1993;199-206.
68. Namer I.J., Steibel J., Piddlesen S.J., et al. Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis. J Neuroimmunol. 54:1994;41-50.
69. Tortorella C., Rocca M.A., Codella C., et al. Disease activity in multiple sclerosis studied with weekly triple dose magnetic resonance imaging. J Neurol. 246:1999;689-692.
70. Miller D.H., Rudge P., Johnson J., et al. Serial gadolinium-enhanced magnetic resonance imaging in multiple sclerosis. Brain. 111:1988;927-939.
71. Thompson A.J., Kermode A.G., MacManus D.G., et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 300:1990;631-634.
72. Harris J.O., Frank J.A., Patronas N., McFarlin D.E., McFarland H.F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 29:1991;548-555.
73. Lai M., Hodgson T., Gawne-Cain M., et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry. 60:1996;339-341.
74. Kermode A.G., Tofts P., Thompson A.J., et al. Heterogeneity of blood-barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 40:1990;229-235.
75. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 42:1997;783-793.
76. van Waesberghe J.H.T.M., van Walderveen M.A.A., Castelijns J.A., et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetisation transfer MR. Am J Neuroradiol. 19:1998;675-683.
77. Filippi M., Rocca M.A., Rizzo G., et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different dose of gadolinium. Neurology. 50:1998;1289-1293.
78. Silver N.C., Tofts P.S., Symms M.R., Barker G.J., Thompson A.J., Miller D.H. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler. 7:2001;75-82.
79. McFarland H.F., Frank J.A., Albert P.S., et al. Using gadolinium-enhanced magnetic resonance imaging to monitor disease activity in multiple sclerosis. Ann Neurol. 32:1992;758-766.
80. Lee M.A., Smith S., Palace J., et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain. 122:1999;1261-1270.
81. Koudriavtseva T., Thompson A.J., Fiorelli M., et al. Gadolinium enhanced MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 62:1997;285-287.
82. Smith M.E., Stone L.A., Albert P.S., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 33:1993;480-489.
83. Molyneux P.D., Filippi M., Barkhof F., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol. 43:1998;332-339.
84. Brex P.A., O'Riordan J.I., Miszkiel K.A., et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology. 53:1999;1184-1190.
85. Stone L.A., Smith E., Albert P.S., et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. Neurology. 45:1995;1122-1126.
86. Losseff N., Kingsley D., McDonald W.I., et al. Clinical and magnetic resonance imaging predictors in primary and secondary progressive MS. Mult Scler. 1:1996;218-222.
87. Coles A.J., Wing M.G., Molyneux P., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 46:1999;296-304.
88. Rudick R.A., Fisher E., Lee J.C., Simon J., Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology. 53:1999;1698-1704.
89. Simon J.H., Jacobs L.D., Campion M.K., et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology. 53:1999;139-148.
90. Filippi M., Rovaris M., Iannucci G., Mennea S., Sormani M.P., Comi G. Whole brain volume changes in progressive MS patients treated with cladribine. Neurology. 55:2000;1714-1718.
91. Davie C.A., Hawkins C.P., Barker G.J., et al. Serial proton magnetic spectroscopy in acute multiple sclerosis lesions. Brain. 117:1994;49-54.
92. Bitsch A., Bruhn H., Vougioukas V., et al. Inflammatory CNS demyelination; histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol. 20:1999;1619-1627.
93. Narayana P.A., Doyle T.J., Lai D., Wolinsky J.S. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis. Ann Neurol. 43:1998;56-71.
94. Weiner H.L., Friedman A., Miller A., et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 12:1994;809-837.
95. Weiner H.L., Mackin G.A., Matsui M., et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 259:1993;1321-1324.
96. Sette A., Alexander J., Ruppert J., et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol. 12:1994;413-431.
97. Anderton S.M., Kissler S., Lamont A.G., Wraith D.C. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur J Immunol. 29:1999;1850-1857.
98. Kappos L., Comi G., Panitch H., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med. 6:2000;1176-1182.
99. Bielekova B., Goodwin B., Richert N., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med. 6:2000;1167-1175.
100. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 19:2001;225-252.
101. Aloisi F., Penna G., Polazzi E., Minghetti L., Adorini L. CD40-CD154 interaction and IFN-g are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. J Immunol. 162:1999;1384-1391.
102. Howard L.M., Miga A.J., Vanderlugt C.L., et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest. 103:1999;281-290.
103. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 6:2000;114.
104. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. J Exp Med. 184:1996;783-788.
105. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 103:1999;1243-1252.
106. Brod S.A., Benjamin D., Hafler D.A. Restricted T cell expression of IL-2, IFN-g mRNA in human inflammatory disease. J Immunol. 147:1991;810-815.
107. Windhagen A., Newcombe J., Dangond F., et al. Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 182:1995;1985-1996.
108. Comabella M., Balashov K., Issazadeh S., Smith D., Weiner H.L., Khoury S.J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 102:1998;671-678.
109. Khoury S.J., Hancock W.W., Weiner H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 176:1992;1355-1364.
110. Bettelli E., Prabhu Das M., Howard E.D., Weiner H.L., Sobel R.A., Kuchroo V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol. 161:1998;3299-3306.
111. Lafaille J.J., Van-de-Keere F., Hsu A.L., et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from disease. J Exp Med. 186:1997;307-312.
112. Genain C.P., Abel K., Belmar N., et al. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2056.
113. Coles A.J., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 354:1999;1691-1695.
114. Selmaj K., Raine C.S. Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue. Ann N Y Acad Sci. 540:1988;568-570.
115. Kuroda Y., Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol. 34:1991;159-164.
116. Baker D., Butler D., Scallon B.J., O'Neill J.K., Turk J.L., Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol. 24:1994;2040-2048.
117. Liu J., Marino M.W., Wong G., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 4:1998;78-83.
118. van Oosten B.W., Barkhof F., Truyen L., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531-1534.
119. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 53:1999;457-465.
120. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 16:1998;137-161.
121. McCartney-Francis N.L., Frazier-Jessen M., Wahl S.M. TGF-beta: a balancing act. Int Rev Immunol. 16:1998;553-580.
122. Calabresi P.A., Fields N.S., Maloni H.W., et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology. 51:1998;289-292.
123. McGuirk P., Mills K.H.G. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol. 23:2002;450-455.
124. Weiner H. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 182:2001;207-214.
125. Lider O., Reshef T., Beraud E., Ben-Nun A., Cohen I.R. Anti-idiotypic network induced by T cell vaccination against EAE. Science. 239:1989;181-183.
126. Medaer R., Stinissen P., Truyen L., Raus J., Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet. 346:1995;807-808.
127. Zhang J.Z., Rivera V.M., Tejada-Simon M.V., et al. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 249:2002;212-218.
128. Vandenbark A.A., Chou Y.K., Whitham R., et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med. 2:1996;1109-1115.